## FOI 0353/2022 Response

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6
months data you have available) with the following treatments:

- Revolade (eltrombopag)
- Nplate (romiplostim)
- Doptelet (avatrombopag)
- Tavlesse (fostamatinib)

Nil (0)

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

Nil (0)

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

rituximab

mycophenolate mofetil

surgery (splenectomy)

Nil (0)

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

The Trust has not participated in the mentioned trials.